3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
236
Carcinoma, Non-Small-Cell Lung
78
Carcinoma, Renal Cell
61
Neoplasm Metastasis
52
Neoplasms
47
Prostatic Neoplasms
34
Uveal Melanoma
29
Lung Neoplasms
28
Pancreatic Neoplasms
27
Carcinoma, Hepatocellular
25
Brain Neoplasms
23
Sarcoma
22
Colorectal Neoplasms
21
Breast Neoplasms
20
Squamous Cell Carcinoma of Head and Neck
18
Small Cell Lung Carcinoma
18
Skin Neoplasms
17
Kidney Neoplasms
17
Diabetes Mellitus, Insulin-Dependent, 12
17
Carcinoma, Transitional Cell
17
Ovarian Neoplasms
15
Triple Negative Breast Neoplasms
14
Urinary Bladder Neoplasms
13
Mesothelioma
13
Uterine Cervical Neoplasms
12
Recurrence
12
Glioblastoma
12
Multiple Myeloma
11
Lymphoma
11
Clear-cell metastatic renal cell carcinoma
11
Interventions
Gemcitabine
13
Albumin-Bound Paclitaxel
8
Taxes
6
130-nm albumin-bound paclitaxel
6
Fluorouracil
5
Oxaliplatin
4
dehydroftorafur
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Leucovorin
3
Irinotecan
3
Losartan
2
Cisplatin
2
tocilizumab
1
selicrelumab
1
niraparib
1
irinotecan sucrosofate
1
indusatumab
1
folfirinox
1
durvalumab
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Tiragolumab
1
Surgical Procedures, Operative
1
Standard of Care
1
Specimen Handling
1
S 1 (combination)
1
Resistance Training
1
Radiotherapy, Image-Guided
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pancreatic Adenocarcinoma
×
Ipilimumab
×
Clear all
NCT03404960
2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2
Completed
104 enrolled
11 charts